Search Results
FBC SUPPORTS PATH FORWARD FOR XLRP TREATMENT
Fighting Blindness Canada is urging Johnson & Johnson to continue pursuing regulatory approval for botaretigene sparoparvovec (bota-vec), a gene therapy for X-linked retinitis pigmentosa (XLRP). This potential treatment has offered new hope...
READ MOREYOUR DOLLARS AT WORK
READ MOREINHERITED RETINAL DISEASES
Over 22,000 Canadians live with inherited retinal diseases (IRDs)—genetic conditions that can lead to vision loss or blindness. Fighting Blindness Canada (FBC) is at the forefront of advancing research, treatments, and support for individuals affected by IRDs. Learn more.
READ MOREVISION HEALTH MONTH
READ MOREPROTECTING VISION RESEARCH IN THE FACE OF POTENTIAL U.S. CUTBACKS
By Jennifer Jones, President and CEO, Fighting Blindness Canada The uncertainty surrounding tariffs and research funding cuts in the United States is sending shockwaves through the global scientific community. The U.S. has...
READ MORERARE DISEASE DAY: AN UPDATE ON INHERITED RETINAL DISEASE RESEARCH
February 28 is Rare Disease Day. In recognition of the day, Fighting Blindness Canada is raising awareness to drive change for those with rare diseases, including an inherited retinal disease (IRD). New...
READ MOREJoin the Fight!
Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.